The current drug development research paradigm is flawed in that it fails to include a diverse and representative patient population. A new approach that begins with a patient-centric mindset, coupled with the use of mobile technology and connected health platforms, will enable research to become less reliant on site-based visits and bring equal access to new investigational therapies for all patients, regardless of geography, ethnicity, sex, or gender.
In this white paper, you will learn about:
- The current diversity gap and limitations in clinical research
- Barriers for underrepresented patient populations
- Breaking barriers with patient-centric approaches and advanced technology
- Foundations for a new clinical research model
- Engaging and protecting patients with technology
Explore related content and topics
White Paper
Cross-Border Enrollment of Rare Disease Patients
Clinical trials in rare diseases present unique challenges unseen in trials for more common conditions. Cross-border enrollment can be key to…
Case Study
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
Blog
Including Children in COVID-19 Trials: Challenges and Opportunities
You may have heard the buzz surrounding a new severe inflammatory condition observed in children that seems to be connected with COVID-19 infection.…